The Founder Banker: A New Paradigm in European HealthTech & MedTech M&A Advisory

Executive Summary
 
The European HealthTech and MedTech M&A advisory landscape is undergoing a structural transformation of lasting significance. For three decades, the provision of M&A advisory services was the exclusive preserve of career financiers, individuals expert in financial engineering, capital markets access, and balance sheet architecture but frequently lacking direct operational experience in the industries they served.
 
A new archetype has emerged to fill that void: the "Founder Banker."
 
These are individuals who have built, scaled, and successfully exited their own ventures before transitioning into strategic advisory roles. Their defining proposition is operational empathy, an understanding of healthcare technology assets that extends beyond financial metrics to encompass the clinical, regulatory, and organisational realities that determine true enterprise value in 2025–2026.
 
This emergence is not a branding exercise or niche trend. It is a structurally necessary response to the increasing complexity of HealthTech and MedTech assets, where AI algorithms, digital therapeutics, and interconnected care platforms exceed the analytical capabilities of generalist finance. As one market analysis summarises: "The 'Founder Banker' model is not merely a niche trend but a necessary evolution in an industry where the complexity of the underlying assets… exceeds the analytical capabilities of generalist finance."
 
Part I: The Macro-Strategic Context
 
The Market Transition: From ZIRP Exuberance to Industrial Maturity
 
The genesis of the Founder Banker lies in a fundamental market reset. Between 2019 and 2022, the Zero Interest Rate Policy (ZIRP) era fuelled a wave of venture-subsidised experimentation. Valuations were driven by growth metrics rather than profitability, and the advisory model was correspondingly straightforward: pitch a growth story, find a buyer.
 
The subsequent contraction was severe. High interest rates and inflation elevated the cost of capital, forcing investors to pivot from "growth at all costs" to a disciplined "flight to quality" where profitability, unit economics, and proven clinical utility are paramount. European healthcare M&A reflected this shift dramatically: despite an 8% decline in deal count in H1 2025, deal value surged by 87%, reaching €31.8 billion, a "bigger cheques, fewer bets" dynamic signalling a maturing market where acquirers prioritise high-quality, high-value assets.
 
The IPO market has contributed to the pressure. M&A transactions accounted for over 94% of all digital health exits globally in H1 2025, leaving M&A as the singular dominant exit route. With public windows effectively closed for most mid-market companies, founders are entirely dependent on the quality of their M&A advisors to crystallise value from years of operational investment.
 
The "Translation Gap": The Structural Failure of Generalist Finance
 
Central to understanding why the Founder Banker emerged is grasping the advisory deficiency it resolves, what practitioners term the "Translation Gap."
 
Historically, healthcare banking and technology banking operated as hermetically sealed silos. Healthcare bankers understood reimbursement codes, clinical trial phases, and the regulatory pathway to market approval. Technology bankers were conditioned to value assets using SaaS metrics: Customer Acquisition Cost (CAC), Lifetime Value (LTV), Annual Recurring Revenue (ARR) and churn rates.
 
Digital Health created a category that fit neither model. A digital therapeutic company might carry the recurring revenue architecture of a software firm while bearing the regulatory burden and clinical risk profile of a pharmaceutical company. Traditional healthcare bankers frequently undervalued the software scalability of these assets; tech bankers underestimated the regulatory "moats" and clinical risk. The result was a systematic market failure: high-quality assets misunderstood by buyers or undervalued during exits.
 
The Founder Banker, having lived this duality as an operator, possesses the "bilingual fluency" required to speak SaaS to technology investors and Clinical Outcomes to healthcare incumbents.
 
Regulatory Darwinism as an Accelerant
 
The complexity of the modern regulatory environment has accelerated demand for advisors with genuine operational literacy. The convergence of the EU Medical Device Regulation (MDR), In Vitro Diagnostic Regulation (IVDR), the EU AI Act (enforcement for high-risk systems commenced March 2026), the European Health Data Space (EHDS), and the NIS2 cybersecurity directive has created a "compliance moat" that is insurmountable for many smaller players.
 
This regulatory environment has produced what analysts describe as "Regulatory Darwinism": a binary filter that separates investable from un-investable assets. Companies that built robust regulatory foundations command significant valuation premiums, while those that followed the "move fast and break things" approach are becoming distressed targets for acqui-hires or forced asset sales. The EHDS alone is expected to generate €11 billion in savings over the next decade by enhancing data accessibility, whilst driving a 20–30% expansion in the digital health sector.
 
Navigating this landscape requires advisors who understand, from direct experience, what it means to manage a Notified Body audit, integrate with NHS procurement infrastructure, or build a quality management system (QMS) that satisfies both ISO 13485 and the AI Act's Article 13 and 14 transparency requirements. Career financiers, however skilled, rarely possess this operational vocabulary.
 
Part II: Defining the Founder Banker Profile
 
Core Characteristics
 
The Founder Banker is distinguished from both traditional investment bankers and informal operator-advisors by four defining characteristics:
 
1. Verified entrepreneurial track record, has personally founded, scaled and achieved a documented exit from one or more HealthTech or MedTech ventures
2. Institutional-grade financial capability, brings technical M&A execution skills developed in bulge-bracket or tier-one boutique environments, including ability to structure complex cross-border transactions
3. Operational empathy, a visceral understanding of the psychological, organisational, and commercial pressures of a founder exit, including experience with NHS procurement, clinical pathway integration and VC relationship dynamics
4. Technical fluency, the ability to assess AI algorithmic defensibility, clinical validation data, and regulatory risk as genuine value drivers rather than footnotes to a financial model.
 
The term "operational empathy" is precise. In the lower mid-market ($25M–$250M), founders are typically selling their life's work. The psychological dimension of the transaction is as significant as the financial one. A banker who has personally navigated the exit process can guide a founder through that experience with a degree of contextual intelligence that a career financier cannot replicate.
 
The "Build, Buy, Partner, Sell" Framework
 
A defining feature of the Founder Banker model is the extension of advisory engagement beyond transaction execution. Rather than engaging at the point of a live process, Founder Bankers characteristically offer a broader "Build, Buy, Partner, Sell" strategic framework that functions as an outsourced corporate development function.
 
This longer-term engagement enables founders to receive strategic guidance on growth and scaling before a transaction is contemplated. In the current "distressed or consolidated" market, this advisory posture has proved especially valuable, enabling buy-side clients to execute "roll-up" strategies that address "vendor sprawl fatigue" among hospital CIOs, and sell-side clients to build the clinical validation evidence that commands premium multiples.
 
The framework also addresses the "build or buy" decision at the corporate level. Rather than simply matching buyers and sellers, Founder Bankers function as strategic architects who help clients assess whether organic development, acquisition, partnership, or divestiture best serves long-term shareholder value, a holistic advisory posture that generalist M&A lacks.
 
Part III: Firm Profiles - The European Ecosystem
 
The Founder Banker movement has produced a taxonomy of specialist boutiques across European markets, each reflecting its regional healthcare and technology ecosystem. The advisory landscape has bifurcated into five broad categories:[4]
 
Nelson Advisors (UK): The Pure-Play Operator Model
 
Nelson Advisors represents the most explicit instantiation of the Founder Banker archetype in the UK market. Co-founded by Lloyd Price and Paul Hemings, the firm operates exclusively in HealthTech (Digital Health, Health IT, Healthcare AI, Healthcare Cybersecurity) with a deliberate focus on the lower-to-mid market ($25M–$250M).
 
Lloyd Price brings over 25 years of experience spanning consumer internet (Yahoo, Kelkoo) and deep HealthTech. He founded Zesty, the UK's first online healthcare marketplace and one of Europe's leading NHS patient engagement platforms, which was acquired by FTSE-listed Induction Healthcare in May 2020. Price also serves as a Health Executive in Residence at UCL Global Business School for Health, cementing academic and clinical influence. His trajectory is critical: he understands consumer engagement metrics (DAUs, MAUs) that technology buyers value, alongside the "scars" of integrating with hospital legacy systems and navigating NHS clinical procurement pathways.
 
Paul Hemings offers a complementary dual profile. His corporate finance background includes tenure at Credit Suisse and Invesco, where he executed over $50 billion in M&A transactions and over $40 billion in equity/financing across more than 15 countries globally. He left the safety of the bulge bracket to co-found Neutrally, a metabolic health venture targeting chronic lifestyle disease, a move that gives him direct founder credibility. Hemings' particular strength lies in structuring complex cross-border deals in "TechBio" and longevity sectors where capital requirements are high and the science is dense.
 
The firm's founding philosophy is "Founders for Founders": the partners' combined four HealthTech exits provide the kind of transactional credibility that goes beyond a standard deal tombstone list, offering a direct experiential parallel to the founders they advise.
 
Clipperton (France): The Research-Led Tech Translator
 
Clipperton has established itself as the premier advisor for the European "Digital Economy," applying rigorous SaaS and digital-economy metrics to HealthTech M&A with a research-led differentiation strategy. Led by Managing Partner Antoine Ganancia, who joined the firm in 2010 and has contributed to over 80 high-profile transactions, Clipperton brings a tech-centric advisory lens to healthcare.
 
Ganancia's background spans strategy consulting (Mars & Co) and Apple, and his advisory work has spanned landmark transactions including DentalMonitoring's $150M growth financing with Merieux Equity and Vitruvian, Inova Software's sale to Carlyle, Withings' $60M fundraise with Gilde Healthcare and Eurazeo, and Brevo's $160M round with Bridgepoint, Bpifrance, and BlackRock. Clipperton's "European Health Tech Monitor" research programme positions it as an intellectual partner to founders, enabling valuation premium arguments grounded in macro themes like "Digital Sovereignty" and AI integration.
 
Clipperton's distinctive expertise is the VC-to-PE bridge: translating a venture-backed "growth story" into the cash flow narrative required by private equity buyers, a critical skill as Europe's maturing HealthTech cohort transitions from growth to profitability orientation.
 
ConAlliance (DACH): The Specialist Healthcare Heavyweight
 
ConAlliance operates as a pure-play healthcare M&A advisory firm with offices in Munich, New York, London, Copenhagen, Chicago, and Hong Kong. In the DACH region, where the industrial MedTech Mittelstand base creates a distinct advisory context, ConAlliance's "founder DNA" is embedded in its sector exclusivity and team composition, which includes physicians and engineers alongside financiers.
 
The firm's deep mastery of European MDR/IVDR compliance dynamics positions it as the trusted advisor for DACH manufacturing companies and family offices navigating "Regulatory Darwinism". Its "relationship-driven" approach reflects a regional business culture where trust is the primary commercial currency and multi-generational family ownership demands advisors who engage as long-term partners rather than transactional intermediaries.
 
Jefferies (Mid-Market Connector): The Conference-Driven Market Maker
 
At a different scale, Tommy Erdei, Joint Global Head of Healthcare Investment Banking and Head of European Healthcare at Jefferies, has built Jefferies' European healthcare franchise through a conference-driven market-making model. By hosting Europe's premier healthcare conferences in London, Jefferies facilitates the high-volume sponsor exits that characterise the mid-market, creating an annual convening mechanism that generates deal flow at institutional scale. Erdei's team represents the institutional infrastructure of the Founder Banker ecosystem rather than its boutique expression.
 
The Scientific Powerhouses: MD Bankers at the Bulge Bracket
 
The Founder Banker trend extends into the mega-cap tier through a parallel phenomenon: the recruitment of medical doctors and PhD scientists into senior investment banking roles. Goldman Sachs's appointment of Philippe Gallone, a trained medical doctor from the University of Lausanne who transitioned from Moelis & Company to become Partner and Head of Healthcare Investment Banking EMEA, exemplifies this. For multi-billion deals involving Big Pharma and AI platforms, the modern healthcare advisor must debate clinical data on par with Chief Scientific Officers. This "Physician-Banker" is effectively a scientific sub-category of the broader Founder Banker movement.
 
Major multi-strategy hedge funds including Balyasny, Point72, and Millennium are aggressively hiring doctors and scientists on the buy-side in Europe, creating an "arms race" for medical talent driven by the need for informational edge in predicting regulatory approvals and clinical outcomes. Founder Bankers and MD Bankers on the sell-side are the necessary response: to sell to a fund managed by clinicians, the advisor must be able to speak their language.
 
Part IV: Valuation in the Founder Banker Era
 
A New Valuation Framework
 
The Founder Banker's operational pedigree has fundamentally altered how HealthTech companies are valued. The conversation has moved away from generic EBITDA multiples toward nuance-rich, sector-specific frameworks that account for technological and regulatory characteristics as primary value drivers.
 
In early 2026, asset valuations are shaped by four key levers: the AI premium, profitability and unit economics, vendor consolidation positioning, and regulatory/compliance fortitude.
 
The "Rule of 40" (Growth % + EBITDA % > 40) has emerged as the dominant capital efficiency benchmark, replacing pure revenue growth as the primary gateway to competitive term sheets. Assets that cannot demonstrate a sub-18-month path to breakeven face down-rounds or distressed exits.
 
The Regulatory Asset Premium
 
A critical insight of the Founder Banker era is the reframing of regulatory certifications as financial assets, not administrative burdens. MDR certificates, AI Act compliance documentation, and EUDAMED registration are now primary determinants of acquirer appetite, particularly for US strategic buyers seeking rapid access to the European market via certified entry points.
 
The scarcity of Notified Bodies has created an 18–24 month regulatory risk profile for non-certified devices, making those with existing certifications highly sought after by US strategic acquirers. Large diagnostics players, Roche, Siemens Healthineers, Abbott, are increasingly engaging in "compliance-driven M&A" specifically to bypass this bottleneck.
 
Distressed M&A and the "Clearing Event"
 
The 2026 market represents a bifurcated "clearing event". On one side, AI-enabled platforms and profitable HealthTech assets command premium multiples of 12x–15x EBITDA. On the other, SMEs in legacy hardware and In Vitro Diagnostics face existential compliance costs, becoming targets for distressed acquisition, carve-outs and insolvency-led restructuring.
 
PE deal volume in European healthcare reached record highs in 2024 and European Healthcare PE deployment value is projected to reach $95 Billion by 2026, with the dominant strategy being "add-on" acquisitions as sponsors build pan-European champions through secondary buyouts and continuation funds. For the Founder Banker, this distressed wave creates a specific demand: guiding a distressed founder through a "soft landing" or acqui-hire with emotional intelligence that large, fee-focused banks rarely provide effectively.
 
Part V: The Broader Ecosystem Implications
 
The Transatlantic Capital Bridge
 
US investor participation in European HealthTech has accelerated dramatically. By 2025, US investors accounted for 62% of participants in European late-stage digital health deals, triple their share from 2023, driving the average late-stage deal size in Europe up 4.1x compared to 2024. This influx of capital from funds managed by increasingly sophisticated scientific investors reinforces the competitive advantage of advisors who can translate European clinical and regulatory narratives for American acquirers.
 
"Vendor Sprawl Fatigue" and the Platform Consolidation Thesis
 
A defining theme of the 2025–2026 vintage is hospital CIOs reporting "vendor sprawl fatigue", the operational burden of managing dozens of disconnected HealthTech point solutions. This is driving consolidation toward comprehensive platforms (e.g., integrating MSK, mental health, and chronic care) that trade at meaningfully higher multiples than standalone "niche apps". The Founder Banker's buy-side advisory capability, specifically the "roll-up" strategy framework, is particularly attuned to this theme, having personally experienced the challenge of building enterprise-scale adoption within health systems.
 
The European HealthTech Market Opportunity
 
The European HealthTech market is valued at approximately $96.68 billion in 2025 and projected to reach $222.22 billion by 2030, representing an 18.11% CAGR. European digital health funding saw a 52% year-on-year increase in H1 2025, reaching $3.4 billion across 182 deals, a regional outperformance against a global trend showing a 13% year-on-year decline over the same period. The UK MedTech market alone is projected to reach £15.7 billion in 2025, growing to £20.5 billion by 2030.
 
Goldman Sachs projects global M&A deal flow could reach $3.9 trillion in 2026, potentially surpassing the 2021 record, with healthcare investment bankers expecting increased transactional activity in 2026 relative to 2025. Half of European dealmakers surveyed expected M&A activity levels to increase over the next 12 months. In this environment, the quality of M&A advisory is a direct determinant of founder outcomes and the Founder Banker's structural advantages compound as deal complexity intensifies.
 
Part VI: Strategic Implications for Founders and Investors
 
The Founder Banker paradigm carries direct actionable implications for stakeholders navigating the European HealthTech M&A market:
 
- Prioritise regulatory assets early - MDR, AI Act compliance, and EUDAMED registration are financial assets, not administrative burdens. Building a "compliance moat" commands measurable valuation premiums in the current market, and advisors with regulatory operating experience can articulate this premium to buyers.
 
- Engage advisors pre-transaction - the "Build, Buy, Partner, Sell" framework is most valuable when applied 12–24 months before a liquidity event, not at the point of a live process. Founder Bankers functioning as outsourced corporate development partners can shape the narrative, clinical validation evidence, and unit economics that drive premium multiples.
 
- Match advisor archetype to asset complexity - for sub $250M digital health and Health IT assets, specialist boutiques with Founder Banker DNA provide the operational empathy and sector granularity that mega-cap generalists cannot match. For multi-billion MedTech deals with complex cross-border and scientific due diligence requirements, the "Physician-Banker" at the bulge bracket provides necessary scale.
 
-  Align with the Rule of 40 - capital efficiency has replaced revenue growth as the primary valuation gateway. Founders should prioritise demonstrating a clear path to breakeven and a healthy Rule of 40 score before initiating a sell-side process.
 
- Position for platform consolidation - building toward an integrated platform proposition, or explicitly positioning as a premium "bolt-on" for a PE-backed aggregator, is likely the optimal shareholder value strategy in a market driven by vendor consolidation.
 
Conclusion
 
The "Founder Banker" represents a permanent structural evolution in European HealthTech and MedTech advisory, not a cyclical trend. As healthcare assets become more technically complex, embedding AI algorithms, clinical data architectures, and regulatory compliance stacks that require genuine operational literacy to assess, the barrier to entry for generalist advisors will continue to rise.
 
The emergence of firms like Nelson Advisors in the UK, Clipperton in France, and ConAlliance in the DACH region reflects a market that has voted with its mandates for advisors who speak both "SaaS" and "Clinical Outcomes." These boutiques have successfully professionalised the role of the operator-advisor, ensuring that the next generation of European HealthTech champions receives guidance commensurate with the complexity of the transactions they must navigate.
 
For founders considering a liquidity event in the 2026–2028 window, the choice of advisor is no longer solely about price maximisation. It is about finding a counterpart who understands the code, the clinical data, the journey and who can translate that story to the increasingly sophisticated, scientifically literate buyer universe now active in European healthcare M&A.